Survey Reveals Strong Public Confidence in Vaccines as Ghana Advances Local Production Plans
A nationwide survey conducted by the National Vaccine Institute has delivered findings that challenge one of public health’s most persistent assumptions: that Ghanaians are broadly sceptical of vaccines. The data tells a different story. Nearly 90 per cent of respondents expressed confidence in vaccines, and more than 71 per cent said they would accept vaccines produced domestically once Ghana’s local manufacturing capacity comes online, now targeted for 2027.
The survey, described as one of the most extensive assessments of vaccine perception ever undertaken in the country, spanned all 16 regions and 55 districts, drawing 13,905 valid responses. Its scope and methodology set it apart from earlier, smaller studies that often relied on convenience sampling and produced more ambiguous results.
Dr Sodzi Sodzi-Tettey, Chief Executive Officer of the National Vaccine Institute, called the findings encouraging but cautioned that confidence alone is insufficient without awareness. Only 14 per cent of respondents knew that Ghana is actively developing local vaccine production capacity. That gap between trust and knowledge represents both a vulnerability and an opportunity. If the government fails to communicate its manufacturing plans effectively, misinformation could fill the vacuum. If it succeeds, the public’s existing confidence could become the foundation for broad acceptance of Ghana-made vaccines.
The survey’s most striking finding may be the one that inverts conventional wisdom about urban and rural attitudes. Highly urbanised regions, including Greater Accra, Ashanti, and Central, recorded lower vaccine acceptance levels than rural communities in northern Ghana and the Oti Region, where trust in vaccines ran higher. This pattern suggests that access to information does not automatically translate into acceptance, a lesson that public health communicators have learned the hard way in other contexts around the world.
Trust in healthcare professionals emerged as a critical variable. More than 87 per cent of respondents expressed confidence in the doctors and nurses who administer vaccines. The Ghana Health Service and the Food and Drugs Authority were also identified as trusted institutions. These figures point to a clear communication strategy: healthcare workers, not politicians or social media influencers, are the most credible advocates for vaccine acceptance. Any public education campaign that sidelines frontline health workers in favour of celebrity endorsements or institutional messaging is likely to underperform.
The findings carry significant implications for Ghana’s broader pharmaceutical ambitions. The country has set a target of beginning local vaccine production by 2027, aligning with the African Union’s goal of producing at least 60 per cent of Africa’s vaccines on the continent by 2040 under the Partnerships for African Vaccine Manufacturing initiative. Ghana has already taken concrete steps toward this goal, including the establishment of the National Vaccine Institute and partnerships with international manufacturers and research institutions.
But the path from aspiration to production is neither short nor simple. The survey identified several practical barriers that could undermine uptake even if public confidence holds. Cost concerns, distance to vaccination centres, and weaknesses in cold chain infrastructure were flagged as persistent challenges, particularly in rural areas where storage and transportation systems remain underdeveloped. Addressing these operational gaps is as important as building the manufacturing plants themselves.
One finding that should command attention from policymakers is the role of national pride. Many respondents indicated that seeing Ghanaian scientists and local factories involved in manufacturing would increase their confidence in domestically produced vaccines. This is not merely sentiment; it is strategic intelligence. The government has an opportunity to build public support for local vaccines by making the manufacturing process visible, celebrating the Ghanaian scientists involved, and treating the first locally produced vaccines as a matter of national achievement rather than routine procurement.
Health experts caution that the survey’s largely positive results should not breed complacency. Vaccine hesitancy is not a fixed state; it shifts in response to events, misinformation, and institutional failures. A single safety incident, whether real or fabricated, could erode years of accumulated trust. The National Vaccine Institute and the Ghana Health Service will need to maintain transparent communication, invest in adverse event monitoring systems, and respond swiftly to public concerns as the manufacturing agenda moves forward.
The survey arrives at a moment when global vaccine supply chains remain fragile, a reality that the COVID-19 pandemic exposed with devastating clarity. Countries that depend entirely on imports for their vaccine supply found themselves at the back of the queue during the pandemic. Ghana’s push for local production is, in part, a response to that experience. The public confidence documented in this survey suggests that Ghanaians understand the stakes and are prepared to support the effort. The challenge now is to match that confidence with competence.
Image Source: MYJOYONLINE
